ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Paragonix to Spotlight Breakthrough Research in Solid Organ Transplantation at the 2025 World Transplant Congress

Presentations at WTC 2025 will highlight real-world data and clinical innovations in solid organ preservation using Paragonix advanced hypothermic preservation and perfusion technologies.

Paragonix Technologies, Inc., a pioneer in advanced organ transplant preservation and surgical services, is proud to announce an impactful presence at the upcoming World Transplant Congress (WTC) 2025, taking place August 2–6 at the Moscone Center in San Francisco, California.

A series of oral and poster presentations at the conference will showcase new clinical findings from the GUARDIAN Registries, in addition to independent clinical analyses, emphasizing the impact of controlled hypothermic preservation on post-transplant outcomes. These studies span multiple organ systems and demonstrate the growing reach and efficacy of Paragonix’s market leading Advanced Organ Preservation solutions.

Paragonix will be featured in two oral presentations and five poster sessions throughout the week, including:

Additionally, Paragonix will be hosting an industry symposium focused on abdominal transplantation:

This event will feature leading transplant experts sharing the latest insights from the GUARDIAN-Liver Registry, case studies on advanced donor liver preservation, and field insights of the KidneyVault Portable Renal Perfusion System, a self-regulated perfusion system that aims to modernize the landscape of kidney transplantation.

“Our presence at WTC 2025 represents a significant milestone in the advancement of our pan-organ transplant preservation technologies and procurement services,” said Dr. Lisa Anderson, President of Paragonix Technologies. “We’re honored to collaborate with leading clinicians and researchers to explore the clinical impact of these innovations and continue to push the boundaries of what’s possible in transplant medicine across all solid organs.”

To visit the Paragonix Technologies exhibit and meet members of their team at WTC, visit booth #314. For more information about Paragonix, visit www.paragonix.com.

About Paragonix Technologies

Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation.

A Getinge company, Paragonix Technologies provides Advanced Organ Preservation (“AOP”) devices that safeguard donor organs during the journey between donor and recipient patients. Their FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with a novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit www.paragonix.com.

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile processing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.

Connect with us on LinkedIn: Paragonix Technologies

Follow us on X (formerly twitter): @ParagonixSherpa

Find us on YouTube: Paragonix SherpaPak

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.